Schonfeld Strategic Advisors LLC bought a new position in shares of IMV Inc. (NYSE:IMV) in the third quarter, HoldingsChannel reports. The firm bought 16,600 shares of the company’s stock, valued at approximately $73,000.
Other hedge funds have also modified their holdings of the company. Wedbush Securities Inc. purchased a new position in shares of IMV during the 3rd quarter worth approximately $52,000. Scotia Capital Inc. raised its stake in shares of IMV by 29.3% during the 3rd quarter. Scotia Capital Inc. now owns 38,739 shares of the company’s stock worth $172,000 after buying an additional 8,776 shares in the last quarter. First City Capital Management Inc. raised its stake in shares of IMV by 72.9% during the 3rd quarter. First City Capital Management Inc. now owns 50,138 shares of the company’s stock worth $179,000 after buying an additional 21,137 shares in the last quarter. Morgan Stanley raised its stake in shares of IMV by 4,036.2% during the 3rd quarter. Morgan Stanley now owns 40,824 shares of the company’s stock worth $182,000 after buying an additional 39,837 shares in the last quarter. Finally, Raymond James & Associates increased its stake in IMV by 143.1% in the 3rd quarter. Raymond James & Associates now owns 45,738 shares of the company’s stock valued at $205,000 after purchasing an additional 26,926 shares in the last quarter.
Shares of NYSE:IMV opened at $3.08 on Friday. The business’s fifty day moving average price is $3.34 and its two-hundred day moving average price is $3.89. IMV Inc. has a one year low of $1.35 and a one year high of $6.82.
IMV (NYSE:IMV) last announced its earnings results on Thursday, November 12th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). The business had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.02 million.
Several research firms recently weighed in on IMV. Raymond James set a $3.00 price objective on IMV and gave the company a “market perform” rating in a research note on Tuesday. Zacks Investment Research downgraded IMV from a “hold” rating to a “sell” rating in a research note on Tuesday, December 22nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the stock. IMV has a consensus rating of “Buy” and an average price target of $7.66.
IMV Inc operates as a clinical-stage biopharmaceutical company. It is developing cancer immunotherapies and vaccines against infectious diseases, including COVID-19. The company's delivery platform (DPX) programs immune cells directly within the human body to produce robust, specific, and sustained target killing capabilities.
Further Reading: Yield Curve
Want to see what other hedge funds are holding IMV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IMV Inc. (NYSE:IMV).
Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.